🇺🇸 FDA
Pipeline program

Sparsentan

AC22084

Phase 2 small_molecule active

Quick answer

Sparsentan for ANCA Associated Vasculitis is a Phase 2 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Travere Therapeutics
Indication
ANCA Associated Vasculitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials